Sigilon Therapeutics

Sigilon Therapeutics

  • Founded: 2016
  • Location: Cambridge, MA
  • Employee range: 50 - 200
  • Clinical stage: RD
  • Therapy area: Diabetes (1)
  • Drug types: END, IMM, NEU, GEN, HEP
  • Lead product: SIG-002
  • Product link:
  • Funding: $145M IPO Dec 2020; $80M Mar 2020; $23.5M A Jun 2017

job board

Short description:

Living Therapeutics

Drug notes:

SIG-XXX RD MPS-1, CNS condition; SIG-007 RD Fabry disease; SIG-018 RD MPS-2, CNS condition; SIG-020 RD MPS-6; undisclosed RD liver disease

Long description:

Contact us to add description.


© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy